Top Monster Stocks in Healthcare for Long-Term Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Eli Lilly's Growth Potential: Eli Lilly (LLY) is positioned to dominate the weight loss drug market, projected to reach nearly $100 billion in the next decade, with recent quarterly revenues exceeding $12 billion, indicating strong growth momentum likely to continue driving company performance.
- AbbVie's New Growth Drivers: AbbVie (ABBV) has successfully launched Skyrizi and Rinvoq ahead of Humira's patent expiration, with recent quarterly revenues surpassing $4 billion and $2 billion respectively, showcasing the company's success in new drug development and boosting investor confidence.
- Abbott's Diversification Advantage: Abbott (ABT) maintains stability through its diversified business units in medical devices, diagnostics, nutrition, and pharmaceuticals, with recent innovations like the AI-powered coronary imaging platform and the acquisition of Exact Sciences solidifying its leadership in the oncology diagnostics market.
- Strategic Value of Long-Term Investment: These monster stocks in the healthcare sector not only demonstrate strong financial performance in the short term but also provide strategic value for long-term holding through continuous innovation and market adaptability, making them ideal for building a future-proof investment portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 88.410
Low
136.00
Averages
148.11
High
169.00
Current: 88.410
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Similac Launches Authentic Parenting Initiative
- Parenting Pressure Survey: In a survey of over 1,000 parents, 93% believe parenthood is the most fulfilling part of life, yet nearly 80% feel pressured by the idealized portrayals of parenting on social media, highlighting the paradox between parenting and social media.
- Advocating Authentic Parenting: Similac has launched the 'Love Without Measure' initiative, collaborating with motherhood experts and influencer moms to share unfiltered parenting stories, helping new parents combat the effects of comparison culture and emphasizing that every parent's effort is enough.
- Dual Impact of Social Media: 78% of new parents agree that social media provides valuable support, and 82% feel less alone, yet 55% worry about being judged for their choices, indicating the significant influence of social media on parenting perceptions.
- Commitment to Supporting Parents: Similac emphasizes that there is no single 'right' way to parent, advocating for judgment-free support throughout the parenting journey, aiming to enhance parents' confidence and sense of belonging through the 'Love Without Measure' initiative.
See More
Top Monster Stocks in Healthcare for Long-Term Gains
- Eli Lilly's Growth Potential: Eli Lilly (LLY) is positioned to dominate the weight loss drug market, projected to reach nearly $100 billion in the next decade, with recent quarterly revenues exceeding $12 billion, indicating strong growth momentum likely to continue driving company performance.
- AbbVie's New Growth Drivers: AbbVie (ABBV) has successfully launched Skyrizi and Rinvoq ahead of Humira's patent expiration, with recent quarterly revenues surpassing $4 billion and $2 billion respectively, showcasing the company's success in new drug development and boosting investor confidence.
- Abbott's Diversification Advantage: Abbott (ABT) maintains stability through its diversified business units in medical devices, diagnostics, nutrition, and pharmaceuticals, with recent innovations like the AI-powered coronary imaging platform and the acquisition of Exact Sciences solidifying its leadership in the oncology diagnostics market.
- Strategic Value of Long-Term Investment: These monster stocks in the healthcare sector not only demonstrate strong financial performance in the short term but also provide strategic value for long-term holding through continuous innovation and market adaptability, making them ideal for building a future-proof investment portfolio.
See More
New Parents Face Pressure Amid Anticipation
- Parental Expectations: New parents generally look forward to parenthood, yet this journey's excitement is often accompanied by pressure and judgment, particularly influenced by idealized portrayals on social media.
- Challenges for Gen Z: For Gen Z parents, despite their desire to embrace the joys of parenthood, the impact of social media amplifies their feelings of pressure, affecting their mental health.
- Impact of Social Media: The portrayal of perfect parenting on social media exacerbates anxiety among new parents, making them feel overwhelmed in their pursuit of idealized parenting methods, which may strain parent-child relationships.
- Interactive News Release: This survey is presented through an interactive multimedia news release format, aiming to raise awareness of the challenges faced by new parents and provide opportunities for support and understanding.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
Abbott's Diversified Business Fuels Growth
- Medical Device Growth: Abbott's medical device segment generated approximately $5.5 billion in revenue during Q1, accounting for nearly half of the company's total sales, showcasing its strong competitive position and market demand in the healthcare sector.
- Diabetes Monitoring Success: The FreeStyle Libre continuous glucose monitoring platform achieved around $2 billion in sales in Q1, with over 7 million users globally, indicating Abbott's significant presence in the rapidly growing diabetes care market.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment reported approximately $578 million in revenue from structural heart products in Q1, with analysts expecting significant market expansion over the next decade due to aging populations, further driving the company's growth.
- Stable Revenue Streams: Abbott's diagnostics and nutrition segments generated about $2.1 billion and $2 billion in sales respectively during Q1, ensuring stability in fluctuating markets and providing funding for future innovation investments.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Structure: Abbott operates across four major segments: medical devices, diagnostics, nutrition, and established pharmaceuticals, with Q1 2023 medical device revenue reaching $5.5 billion, accounting for about 50% of total sales, which has helped the company remain resilient in changing healthcare environments.
- Diabetes Care Growth: Abbott's FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales, with over 7 million users globally, and as the number of diabetes patients is expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment generated about $578 million in Q1 revenue, and with an aging population, analysts expect this market to expand significantly over the next decade, with Abbott's MitraClip and TriClip products helping to capture this growing share.
- Stable Revenue Sources: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Similac providing steady revenue streams that help offset fluctuations in other areas of the business.
See More
Similac Launches Authentic Parenting Initiative
- Parenting Pressure Survey: In a survey of over 1,000 parents, 93% believe parenthood is the most fulfilling part of life, yet nearly 80% feel pressured by the idealized portrayals of parenting on social media, highlighting the paradox between parenting and social media.
- Advocating Authentic Parenting: Similac has launched the 'Love Without Measure' initiative, collaborating with motherhood experts and influencer moms to share unfiltered parenting stories, helping new parents combat the effects of comparison culture and emphasizing that every parent's effort is enough.
- Dual Impact of Social Media: 78% of new parents agree that social media provides valuable support, and 82% feel less alone, yet 55% worry about being judged for their choices, indicating the significant influence of social media on parenting perceptions.
- Commitment to Supporting Parents: Similac emphasizes that there is no single 'right' way to parent, advocating for judgment-free support throughout the parenting journey, aiming to enhance parents' confidence and sense of belonging through the 'Love Without Measure' initiative.
See More
Top Monster Stocks in Healthcare for Long-Term Gains
- Eli Lilly's Growth Potential: Eli Lilly (LLY) is positioned to dominate the weight loss drug market, projected to reach nearly $100 billion in the next decade, with recent quarterly revenues exceeding $12 billion, indicating strong growth momentum likely to continue driving company performance.
- AbbVie's New Growth Drivers: AbbVie (ABBV) has successfully launched Skyrizi and Rinvoq ahead of Humira's patent expiration, with recent quarterly revenues surpassing $4 billion and $2 billion respectively, showcasing the company's success in new drug development and boosting investor confidence.
- Abbott's Diversification Advantage: Abbott (ABT) maintains stability through its diversified business units in medical devices, diagnostics, nutrition, and pharmaceuticals, with recent innovations like the AI-powered coronary imaging platform and the acquisition of Exact Sciences solidifying its leadership in the oncology diagnostics market.
- Strategic Value of Long-Term Investment: These monster stocks in the healthcare sector not only demonstrate strong financial performance in the short term but also provide strategic value for long-term holding through continuous innovation and market adaptability, making them ideal for building a future-proof investment portfolio.
See More
New Parents Face Pressure Amid Anticipation
- Parental Expectations: New parents generally look forward to parenthood, yet this journey's excitement is often accompanied by pressure and judgment, particularly influenced by idealized portrayals on social media.
- Challenges for Gen Z: For Gen Z parents, despite their desire to embrace the joys of parenthood, the impact of social media amplifies their feelings of pressure, affecting their mental health.
- Impact of Social Media: The portrayal of perfect parenting on social media exacerbates anxiety among new parents, making them feel overwhelmed in their pursuit of idealized parenting methods, which may strain parent-child relationships.
- Interactive News Release: This survey is presented through an interactive multimedia news release format, aiming to raise awareness of the challenges faced by new parents and provide opportunities for support and understanding.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
Abbott's Diversified Business Fuels Growth
- Medical Device Growth: Abbott's medical device segment generated approximately $5.5 billion in revenue during Q1, accounting for nearly half of the company's total sales, showcasing its strong competitive position and market demand in the healthcare sector.
- Diabetes Monitoring Success: The FreeStyle Libre continuous glucose monitoring platform achieved around $2 billion in sales in Q1, with over 7 million users globally, indicating Abbott's significant presence in the rapidly growing diabetes care market.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment reported approximately $578 million in revenue from structural heart products in Q1, with analysts expecting significant market expansion over the next decade due to aging populations, further driving the company's growth.
- Stable Revenue Streams: Abbott's diagnostics and nutrition segments generated about $2.1 billion and $2 billion in sales respectively during Q1, ensuring stability in fluctuating markets and providing funding for future innovation investments.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Structure: Abbott operates across four major segments: medical devices, diagnostics, nutrition, and established pharmaceuticals, with Q1 2023 medical device revenue reaching $5.5 billion, accounting for about 50% of total sales, which has helped the company remain resilient in changing healthcare environments.
- Diabetes Care Growth: Abbott's FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales, with over 7 million users globally, and as the number of diabetes patients is expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment generated about $578 million in Q1 revenue, and with an aging population, analysts expect this market to expand significantly over the next decade, with Abbott's MitraClip and TriClip products helping to capture this growing share.
- Stable Revenue Sources: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Similac providing steady revenue streams that help offset fluctuations in other areas of the business.
See More
